Ventyx Biosciences' VTX3232 demonstrates significant reduction in heart disease risk markers in Phase 2 trial, with strong anti-inflammatory effects and good safety profile.
Molina Healthcare drastically lowered its 2025 profit outlook, blaming unexpectedly high medical costs, especially in its Marketplace (Obamacare) business.
Intuitive Surgical beats Q3 earnings expectations with strong da Vinci and Ion system sales, driving shares up 14% and prompting multiple analyst upgrades.
Armata's AP-SA02 bacteriophage cocktail showed high cure rates and zero relapse in a Phase 2 trial for complicated Staphylococcus aureus bacteremia (SAB), signaling a potential new standard of care.
Arcturus Therapeutics shares drop sharply after interim trial data on its inhaled mRNA therapy for cystic fibrosis show mixed results—some signs of mucus reduction but limited lung function improvement.
Alkermes (ALKS) announces $2.1B acquisition of Avadel Pharmaceuticals (AVDL) to gain approved narcolepsy drug Lumryz and enter the growing sleep medicine market. Deal expected Q1 2026.
